1998Seminars in NeurologyRequires access

Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy

Richard J. Barohn, David Saperstein

Open publisher page 68 citations

Abstract

Acute and chronic inflammatory demyelinating polyneuropathies represent an important group of disorders. Although the acute form is more common, all clinical neurologists will eventually encounter patients with these disorders. Acute inflammatory demyelinating polyneuropathy, or Guillain-Barré syndrome, is the most common cause of acute generalized weakness. Chronic inflammatory demyelinating polyneuropathy, characterized by progressive or relapsing weakness, is important to recognize because it represents a significant number of all initially undiagnosed acquired neuropathies. There are a variety of reasonable therapies available for both of these acquired demyelinating neuropathies. Recently much has been learned about pathogenesis and treatment. This review describes the clinical presentations, laboratory studies, diagnostic criteria, treatment, and prognosis for each disorder.

About this research paper

What this paper is about

Acute and chronic inflammatory demyelinating polyneuropathies represent an important group of disorders. Although the acute form is more common, all clinical neurologists will eventually encounter patients with these disorders. Acute inflammatory demyelinating polyneuropathy, or Guillain-Barré syndrome, is the most common cause of acute generalized weakness. Chronic inflammatory demyelinating polyneuropathy, characterized by progressive or relapsing weakness, is important to recognize because it represents a significant number of all initially undiagnosed acquired neuropathies. There are a variety of reasonable therapies available for both of these acquired demyelinating neuropathies. Recently much has been learned about pathogenesis and treatment. This review describes the clinical presentations, laboratory studies, diagnostic criteria, treatment, and prognosis for each disorder.

Why it matters

OpenAlex reports 68 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Acute and chronic inflammatory demyelinating polyneuropathies represent an important group of disorders. Although the acute form is more common, all clinical neurologists will eventually encounter patients with these disorders. Acute inflammatory demyelinating polyneuropathy, or Guillain-Barré syndrome, is the most common cause of acute generalized weakness. Chronic inflammatory demyelinating polyneuropathy, characterized by progressive or relapsing weakness, is important to recognize because it represents a significant number of all initially undiagnosed acquired neuropathies. There are a variety of reasonable therapies available for both of these acquired demyelinating neuropathies. Recently much has been learned about pathogenesis and treatment. This review describes the clinical presentations, laboratory studies, diagnostic criteria, treatment, and prognosis for each disorder.

Key concepts: Medicine, Chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, Polyneuropathy, Dermatology, Immunology, Pathology, Antibody

Related papers

Back to paper searchBrowse research topicsOriginal source
Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy — Research Paper | ScholarLens